Everton Mandley

MTAP Deletions in Cancer Create Vulnerability to Targeting of the MAT2A/PRMT5/RIOK1 Axis

Katya Marjon, Michael J. Cameron, Phong Quang et al. · Cell Reports · 2016 · 447 citations · Full text

Medicine, Cancer Biology, Oncology +17

MAT2A Inhibition Blocks the Growth of MTAP-Deleted Cancer Cells by Reducing PRMT5-Dependent mRNA Splicing and Inducing DNA Damage

Peter Kalev, Marc L. Hyer, Zenon Konteatis et al. · Cancer Cell · 2021 · 234 citations

Life Sciences, Molecular Biology, Oncology +7

Discovery of AG-270, a First-in-Class Oral MAT2A Inhibitor for the Treatment of Tumors with Homozygous <i>MTAP</i> Deletion

Zenon Konteatis, Jeremy Travins, Katya Marjon et al. · Journal of Medicinal Chemistry · 2021 · 97 citations · Full text

Pharmacy, Oncology, Pharmacology +16

Leveraging Structure-Based Drug Design to Identify Next-Generation MAT2A Inhibitors, Including Brain-Penetrant and Peripherally Efficacious Leads

Mingzong Li, Zenon Konteatis, N. Nagaraja et al. · Journal of Medicinal Chemistry · 2022 · 37 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +16